Irene is the Director of Drug Discovery at Verge Genomics in San Francisco, CA. She has spent her career in early drug discovery in neuroscience and oncology having led multiple programs, one of which was of a novel opioid analgesic with demonstrated efficacy in Phase 3 clinical trials. At Verge Genomics, she works with biologists and computational scientists to test artificial intelligence enabled machine learning predictions at the bench to identify novel therapeutics in neurodegenerative diseases.
Savan Devani is the Founder and CEO of BioTrillion, a health technology company developing BioEngine4D to digitally detect developing diseases.
Previously, Savan spent the majority of his 15 year career in the Life Sciences industry working as a healthcare investment banker with hundreds of innovators. From Analyst through Managing Director, Savan led 40 deals, totaling $35 billion, across the drug, diagnostic, and device spectrum. Savan began his career as a little bioengineer in a big lab at Life Technologies.
Savan graduated with a B.S.E. in Bioengineering from the University of California at Berkeley and a M.S.E. in Bioengineering from the University of Pennsylvania.
A deeply personal experience later in life made Savan truly realize how much in healthcare needed to change – his mother was suddenly diagnosed with stage IVb cancer – which compelled asking “where were all the signs” and “isn’t there a better way,” which led to BioTrillion.
Associate Director Materials and Innovation
Ronald Dorenbos – Associate Director Materials and Innovation
As Associate Director of Materials & Innovation and as a member of Takeda’s Digital Strategy team for Neuroscience Ronald helps Takeda with its technology and innovation strategy, identifying technologies that can benefit Takeda’s core areas Oncology, Neuroscience and Gastroenterology. Earlier, at the Life Science division of PA Consulting, Ronald led projects for some of the world’s top 10 pharmaceutical companies that included projects around strategy, commercialization, and digital health and at his company BioFrontline he provided management, strategy and commercial advice to life sciences companies around the world. After obtaining MAs in Biotechnology and Molecular Biology and a Ph.D. in Pharmaceutical Biology he spent six years at Harvard studying Parkinson’s, Schizophrenia and the genetics of aggressive behavior before making the transition to industry. Ronald is a keen follower of applications of AI and deep learning in pharma and healthcare and is the founder of the LinkedIn group 'AI – Artificial Intelligence.'
Therapeutic Area Head, Immunology, at Global Pharmacovigilance and Epidemiology
Dr. Douglas Fleming – Therapeutic Area Head, Immunology, at Global Pharmacovigilance and Epidemiology
Physician and epidemiologist.
Doug received his BA in humanities and physics from Yale, and served as a Peace Corps Volunteer teacher in Kenya. He earned an MD from Yale Medical School, and did his residency in Internal Medicine at Mount Auburn Hospital of Harvard Medical School. He did his fellowship in Epidemiology with the Epidemic Intelligence Service of the United States Centers for Disease Control (CDC) in Atlanta, Georgia.
Doug worked in public health for 15 years, teaching internal medicine at an inner-city health center, and later serving in CDC’s Global AIDS Program in Botswana (southern Africa), running clinical trials for HIV and TB medications. When he returned to the United States in 2007, he joined Bristol-Myers Squibb, where he worked for 5 years on clinical development in diabetes, and he developed epidemiologic tools for safety analyses. He joined Lexicon Pharmaceuticals in 2013 as Medical Lead for telotristat etiprate, and for 3 years led development of this new drug for a particular rare cancer (carcinoid tumor). The drug aims to reduce the severe effects of this tumor on the heart muscle. The drug’s clinical trials were successful, and were just published in the Journal of Clinical Oncology. In 2016, he returned to Bristol-Myers Squibb, where he leads a group of physicians who track the safety of BMS’s products in immunology. He is also leading an effort to provide advanced epidemiological and clinical tools to detect and understand potential safety signals. His work concentrates on ongoing safety analysis during development of new medications.
Senior Manager A.I./Machine Learning Development
Kevin Hua – Senior Manager A.I./Machine Learning Development
Dr. (Kevin) Hua has 20 years of experience working in design and development of AI/Machine Learning applications in healthcare, insurance, banking, retails and manufacturing industries. He is currently a senior manager with the Digital Health Intelligence Group of Bayer, responsible for developing AI/ML applications. Prior to Bayer, he was a machine learning specialist at Deloitte Consulting and a research manager of AI at Center for Advanced Research of PwC. His work in analytics has won the Analytics Leadership Award from IU Kelley School of Business in 2014 and INFORMS Data Mining contest in 2008.
Christopher Jordan is principally responsible for all aspects of Click’s technology strategy and development, with product, design, engineering, and data science teams reporting into him. Mr. Jordan has over nine years of technology management experience and played a key role as an engineering manager at Bloomberg LP prior to joining Click. Mr. Jordan holds a BSE in Computer Engineering from the University of Michigan.
Rishi Madhok – Chief Executive Officer and Co-Founder
Rishi Madhok, M.D., is a board-certified emergency medicine physician who focuses on bridging the gap between technology and medicine. Prior to founding BitMED, Rishi partnered with the Harvard Humanitarian Initiative, Rishi was the technical lead expert in the development of portable medical software to analyze the health needs of refugee and third world populations.
Rishi’s research has led to significant medical innovations and has been presented both nationally and internationally. Rishi was previously Director of Clinical Informatics at the University of Pennsylvania hospital. He has also been a medical advisor to multiple small and medium stage companies, including Warby Parker, Wellzio, and Good Parents Inc.
Rishi obtained his medical degree at Columbia University College of Physicians and Surgeons and completed his emergency medicine residency training at NewYork-Presbyterian Hospital — the University Hospital of Columbia & Cornell. Rishi was among the earliest physicians to become board certified in the emerging field of Clinical Informatics.
, MBA, Ph.D.
Senior Director, Head of Digital Health Care Initiatives
SUNOVION PHARMACEUTICALS INC.
Georgia Mitsi – Senior Director, Head of Digital Health Care Initiatives
SUNOVION PHARMACEUTICALS INC.
Georgia Mitsi, MBA, Ph.D., is Senior Director, Head of Digital Health Care Initiatives at Sunovion, which is focused on the innovative application of science, medicine and technologies to help people with serious psychiatric, neurological and respiratory conditions.
Dr. Mitsi oversees initiatives that focus on integrating digital health technologies into Sunovion’s solutions to contribute towards the goals to significantly to empower patients to better manage their symptoms and improve quality of life for those who are living with chronic medical conditions. She also contributes to Sunovion’s support of public-private partnerships designed to accelerate digital health care solutions.
Dr. Mitsi was named as a 2018 PharmaVOICE 100 inspirational leader, recognized as a digital expert and transformational leader who is moving the industry forward using a variety of digital strategies and tools. She was also recognized by CenterWatch as a Top 20 innovator. Dr. Mitsi is a hands-on digital innovator with expertise in health outcomes and health economics research and experience in pharmaceutical and healthcare industry consulting. Prior to joining Sunovion, Dr. Mitsi was Founder and Chief Executive Officer of Apptomics, which provided scientifically-validated mobile applications. Previously, she served in health economics and clinical research roles at United BioSource Corporation and in health research services at Humana.
Dr. Mitsi is an active blogger on a variety of digital healthcare topics and has authored numerous scientific publications and two novels. She has been a long-time supporter and mentor to digital health start-up companies and has served as a Judge and Mentor as part of the MIT Enterprise Forum. Dr. Mitsi holds an MBA in international business from the University of Miami School of Business Administration, and a Ph.D. in Pharmacoepidemiology and MSc in Applied Medical Sciences from the University of Patras.
Executive Director, Center for Health Systems Innovation (CHSI)
OKLAHOMA STATE UNIVERSITY
William Paiva – Executive Director, Center for Health Systems Innovation (CHSI)
OKLAHOMA STATE UNIVERSITY
William D. Paiva, Ph.D., is Executive Director of Oklahoma State University’s Center for Health Systems Innovation (CHSI). The Center is focused on transforming rural and Native America health through the implementation of innovative care delivery and IT solutions. Within CHSI, the Institute for Predictive Medicine is applying advanced analytics to the largest health care database which includes clinical information for over 63 million patients covering 16 years.
Prior to joining Oklahoma State University, Dr. Paiva was a partner, joined Sevin Rosen Funds, a fund with over $2 billion under management, where he brought more than 20 years of venture-capital, biomedical-industry and management-consulting experience to the firm. William specialized in identifying early-stage venture opportunities at the intersection of traditional technology sectors and healthcare. He also used his healthcare expertise and network to assist Sevin Rosen portfolio companies developing applications and services for the healthcare market. Prior to Sevin Rosen, William was a partner at Chisholm Private Capital Partners, where he managed a $100 million fund focused on healthcare and IT. He also worked as a manager at the Oklahoma Life Science Fund, managing $15 million and making investments in diagnostics, services and therapeutics firms.
Before that, William served as a management consultant for the Life Sciences Industry Group at Pittiglio Rabin Todd & McGrath, later acquired by PriceWaterhouseCoopers, where he consulted with the top five pharmaceutical companies on product-development and technology-management projects. William also served as an investment banking associate at JP Morgan in New York, providing strategic and investment banking advisory services to Fortune 100 healthcare companies.
William holds a Ph.D. in molecular biology from the University of Oklahoma; an MBA from Dartmouth College’s Amos Tuck School of Business; a master’s degree in microbiology and immunology from the University of Oklahoma Health Science Center; and a B.S. in microbiology from the University of Oklahoma.
Aris Persidis is President and co-founder of Biovista. He is responsible for outreach and business development and has helped design the specifications and tracking of the Project Prodigy AI. Aris authored the Industry Trends column for Nature Biotechnology, was a judge for the 2011 Top-10 Innovations of The Scientist and served as the inaugural co-Editor-in-Chief of Drug Rescue, Repurposing and Repositioning. He was SVP, Business Development for Upstate Bio (acquired by Serologicals), Managing Director of Rheogene (acquired by Intrexon), and participated in the cofounding of Cellzome (acquired by GSK), and Anadys (acquired by Roche). Aris was also adjunct assistant professor at Wharton and holds a Ph.D. in biochemistry from Cambridge.
Malaikannan Sankarasubbu is the VP of AI Research in Saama Technologies. He is currently working on optimizing and accelerating clinical trials using Artificial Intelligence. He specializes in deriving insights with unstructured data like text and images. He previously was Founder and CTO for Datalog.ai creators of MyPolly, a chatbot building platform with its own Natural Language Understanding Engine where he built a community of 1,200 active developers, aka chatbot builders, around MyPolly. Malaikannan was part of the Enterprise Architecture team in Optum and Cognizant Technology Solutions. He understands Healthcare and is passionate about advancing more applications of Deep Learning in Healthcare and Life Sciences. Malaikannan loves building community; he along with few others built a community around Keras and he also created an active forum Indian Deep Learning Initiative which has over 4,500 members. Malaikannan actively shares his knowledge in Meetups and conferences and loves to blog about Artificial Intelligence at malaikannan.io.
Dr. Kelly Stanton is a bioinformatics expert and visiting scientist at Yale University, applying statistics, signal processing and mathematics to analyze DNA sequencing data since 2010. He earned his B.S. in Biomedical Engineering from the University of Texas at Austin and Ph.D. in Bioinformatics at Yale University in 2015. Kelly has published work ranging from bioinformatics applications to new mathematical techniques for general data science use. His post-doctoral work is focused on pioneering new deep learning based algorithms for unsupervised and semi-supervised learning. Currently, Kelly designs predictive analytics for clinical outcomes based on medical IOT data at Potrero Medical. He currently resides in San Francisco, CA.
Senior Director, Product Management
Luke Stewart – Senior Director, Product Management
In his role as Senior Director of Product Management at Saama, Luke drives the vision and strategy for Saama’s Life Sciences solutions and Fluid Analytics for Life Sciences data management offering. He has a passion for creating user-centered, analytic solutions and is excited to be doing so in the life sciences space. While at Cisco, he helped drive a pre-revenue internal startup to over 3500 customers in 3 years. Prior to Cisco, Luke co-founded a startup and worked at NASA. He has his MBA from Stanford Graduate School of Business and a BA in Math and Computer Science from Duke University.
Vice President, Digital Health and Business Operations
Charles Wolfus – Vice President, Digital Health and Business Operations
As MyoKardia’s head of Digital Health, Charles Wolfus is on a mission to improve patient lives by applying sensors, social media, mobile technology, and artificial intelligence in clinical trials and daily life.
In 2016, Charles led MyoKardia’s multidisciplinary team in the world’s first use of wearables in an interventional clinical study. MyoKardia’s phase 2 PIONEER-HCM clinical trial used these sensors to capture PPG data as an exploratory endpoint. Through subsequent machine-learning analysis, MyoKardia was able to detect HCM with greater than 95% accuracy.
Charles is a recognized thought leader in the fusion of wearable technology and its use in clinical trials. He passionately believes that these technologies will improve healthcare for all. Charles has been a technology leader in biotech for nearly 20 years and a featured a speaker at international digital health symposia. He is licensed to practice law in the State of California.